Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects

Neuropsychopharmacology

Volumn 37, Issue 5, 2012, Pages 1083-1091

  Wee, Sunmee ^a   Hicks, Martin J ^b   De, Bishnu P ^b   Rosenberg, Jonathan B ^b   Moreno, Amira Y ^a   Kaminsky, Stephen M ^b   Janda, Kim D ^a   Crystal, Ronald G ^b   Koob, George F ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cocaine; locomotor activity; rats; reinstatement; self administration; vaccine

Indexed keywords

6 3 (BENZOYLOXY 8 METHYL 8 AZABICYCLO [3.2.1] OCTANE 2 CARBOXAMIDO HEXANOIC ACID; COCAINE; N (4 METHOXYPHENYLACETYL)DEHYDROALANINE; PSYCHOSTIMULANT AGENT; TRITIUM; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; BEHAVIOR CHANGE; BLOOD; BRAIN; CONTROLLED STUDY; DRUG SEEKING BEHAVIOR; GENE TRANSFER; LOCOMOTION; MALE; MOTIVATION; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RAT; SENSITIZATION; SEROTYPE; VACCINATION;

ADENOVIRIDAE; ANALYSIS OF VARIANCE; ANIMALS; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; COCAINE-RELATED DISORDERS; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; DOPAMINE UPTAKE INHIBITORS; EXTINCTION, PSYCHOLOGICAL; GENETIC VECTORS; HAPTENS; IMMUNOGLOBULIN G; MALE; METHAMPHETAMINE; MOTOR ACTIVITY; RADIOIMMUNOASSAY; RATS; RATS, WISTAR; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION; TIME FACTORS; TRANSFER (PSYCHOLOGY); TRITIUM; VACCINATION;

EID: 84858334481     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.200     Document Type: Article

References (35)

1. Anton B, Leff P (2006). A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine 24: 3232-3240.
2. Anton B, Salazar A, Flores A, Matus M, Marin R, Hernandez JA et al. (2009). Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccin 5: 214-229.
3. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR (1974). Changes in heroin self-administration by a rhesus monkey after morphine immunization. Nature 252: 708-710.
4. Caine SB, Koob GF (1994). Effects of dopamine D-1 and D-2 antagonists on cocaine self-administration under different schedules of reinforcement in the rat. J Pharmacol Exp Ther 270: 209-218.
5. Carrera MR, Ashley JA, Parsons LH, Wirsching P, Koob GF, Janda KD (1995). Suppression of psychoactive effects of cocaine by active immunization. Nature 378: 727-730.
6. Carrera MR, Ashley JA, Wirsching P, Koob GF, Janda KD (2001). A second-generation vaccine protects against the psychoactive effects of cocaine. Proc Natl Acad Sci USA 98: 1988-1992.
7. Carrera MR, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD (2000). Cocaine vaccines: Antibody protection against relapse in a rat model. Proc Natl Acad Sci USA 97: 6202-6206.
8. Cerny T (2005). Anti-nicotine vaccination: Where are we? Recent Results Cancer Res 166: 167-175.
9. Duryee MJ, Bevins RA, Reichel CM, Murray JE, Dong Y, Thiele GM et al. (2009). Immune responses to methamphetamine by active immunization with peptide-based, molecular adjuvant-containing vaccines. Vaccine 27: 2981-2988.
10. Edwards S, Whisler KN, Fuller DC, Orsulak PJ, Self DW (2007). Addiction-related alterations in D1 and D2 dopamine receptor behavioral responses following chronic cocaine self-administration. Neuropsychopharmacology 32: 354-366.
11. Epstein DH, Preston KL, Stewart J, Shaham Y (2006). Toward a model of drug relapse: An assessment of the validity of the reinstatement procedure. Psychopharmacology (Berlin) 189: 1-16.
12. Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ et al. (1996). Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 2: 1129-1132.
13. Gentry WB, Ruedi-Bettschen D, Owens SM (2009). Development of active and passive human vaccines to treat methamphetamine addiction. Hum Vaccin 5: 206-213.
14. Haney M, Gunderson EW, Jiang H, Collins ED, Foltin RW (2010). Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol Psychiatry 67: 59-65.
15. Haney M, Kosten TR (2004). Therapeutic vaccines for substance dependence. Expert Rev Vaccines 3: 11-18.
16. Harris AC, Pentel PR, Lesage MG (2007). Prevalence, magnitude, and correlates of an extinction burst in drug-seeking behavior in rats trained to self-administer nicotine during unlimited access (23 h/day) sessions. Psychopharmacology (Berlin) 194: 395-402.
17. Hicks MJ, De BP, Rosenberg JB, Davidson JT, Moreno AY, Janda KD et al. (2011). Cocaine analog coupled to disrupted adenovirus: A vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther 19: 612-619.
18. Kantak KM, Collins SL, Bond J, Fox BS et al. (2001). Time course of changes in cocaine self-administration behavior in rats during immunization with the cocaine vaccine IPC-1010. Psychopharmacology (Berlin) 153: 334-340.
19. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS (2000). Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berlin) 148: 251-262.
20. Keyler DE, Roiko SA, Earley CA, Murtaugh MP, Pentel PR (2008). Enhanced immunogenicity of a bivalent nicotine vaccine. Int Immunopharmacol 8: 1589-1594.
21. Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J et al. (2002). Human therapeutic cocaine vaccine: Safety and immunogenicity. Vaccine 20: 1196-1204.
22. Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD, Gardner T et al. (2009). Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: A randomized, double-blind, placebo-controlled efficacy trial. Arch Gen Psychiatry 66: 1116-1123.
23. McClurkan MB, Valentine JL, Arnold L, Owens SM (1993). Disposition of a monoclonal anti-phencyclidine Fab fragment of immunoglobulin G in rats. J Pharmacol Exp Ther 266: 1439-1445.
24. Mets B, Winger G, Cabrera C, Seo S, Jamdar S, Yang G et al. (1998). A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc Natl Acad Sci USA 95: 10176-10181.
25. Moreno AY, Azar MR, Warren NA, Dickerson TJ, Koob GF, Janda KD (2010). A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol Pharmacol 7: 431-441.
26. Orson FM, Kinsey BM, Singh RA, Wu Y, Kosten TR (2009). Vaccines for cocaine abuse. Hum Vaccin 5: 194-199.
27. Owens SM, Mayersohn M (1986). Phencyclidine-specific Fab fragments alter phencyclidine disposition in dogs. Drug Metab Dispos 14: 52-58.
28. Richardson NR, Roberts DC (1996). Progressive ratio schedules in drug self-administration studies in rats: A method to evaluate reinforcing efficacy. J Neurosci Methods 66: 1-11.
29. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W et al. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68: 143-155.
30. Stewart J (2000). Pathways to relapse: The neurobiology of drugand stress-induced relapse to drug-taking. J Psychiatry Neurosci 25: 125-136.
31. Valentine JL, Arnold LW, Owens SM (1994). Anti-phencyclidine monoclonal Fab fragments markedly alter phencyclidine pharmacokinetics in rats. J Pharmacol Exp Ther 269: 1079-1085.
32. Valentine JL, Owens SM (1996). Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats. J Pharmacol Exp Ther 278: 717-724.
33. Wee S, Specio SE, Koob GF (2007). Effects of dose and session duration on cocaine self-administration in rats. J Pharmacol Exp Ther 320: 1134-1143.
34. Xu Y, Hixon MS, Yamamoto N, McAllister LA, Wentworth AD, Wentworth P Jr et al. (2007). Antibody-catalyzed anaerobic destruction of methamphetamine. Proc Natl Acad Sci USA 104: 3681-3686.
35. Yahyavi-Firouz-Abadi N, See RE (2009). Anti-relapse medications: Preclinical models for drug addiction treatment. Pharmacol Ther 124: 235-247.